PMID- 24373190
OWN - NLM
STAT- MEDLINE
DCOM- 20150309
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 16
IP  - 7
DP  - 2014 Jul
TI  - Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical 
      implications for type 2 diabetes mellitus.
PG  - 588-601
LID - 10.1111/dom.12253 [doi]
AB  - Recent advances in therapies for the treatment of type 2 diabetes mellitus (T2DM) 
      have led to the development of glucagon-like peptide-1 receptor agonists (GLP-1 
      RAs), which, unlike insulin and sulphonylurea, are effective, with a low risk of 
      hypoglycaemia. Lixisenatide is recommended as a once-daily GLP-1 RA for the 
      treatment of T2DM. In persons with T2DM, lixisenatide 20 microg once-daily given by 
      bolus subcutaneous injection improves insulin secretion and suppresses glucagon 
      secretion in a glucose-dependent manner. Compared with the longer-acting GLP-1 RA 
      liraglutide, lixisenatide achieved a significantly greater reduction in 
      postprandial plasma glucose (PPG) during a standardized test breakfast in persons 
      with T2DM otherwise insufficiently controlled on metformin alone. This is 
      primarily due to the greater inhibition of gastric motility by lixisenatide 
      compared with liraglutide. The efficacy and safety of lixisenatide was evaluated 
      across a spectrum of T2DM in a series of phase III, randomized, 
      placebo-controlled trials known as the GetGoal programme. Lixisenatide 
      monotherapy or as add-on to oral antidiabetic agents or basal insulin achieved 
      significant reductions in glycated haemoglobin, PPG and fasting plasma glucose, 
      with either weight loss or no weight gain. The most frequent adverse events were 
      gastrointestinal and transient in nature. Lixisenatide provides an easy, 
      once-daily, single-dose, add-on treatment to oral antidiabetic agents or basal 
      insulin for the management of T2DM, with little or no increased risk of 
      hypoglycaemia and a potential beneficial effect on body weight.
CI  - (c) 2013 John Wiley & Sons Ltd.
FAU - Bolli, G B
AU  - Bolli GB
AD  - Department of Medicine, University of Perugia, Hospital S.M. della Misericordia, 
      Perugia, Italy.
FAU - Owens, D R
AU  - Owens DR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140120
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Glucagon)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 74O62BB01U (lixisenatide)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Blood Glucose/*drug effects
MH  - Clinical Trials, Phase III as Topic
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Administration Schedule
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Glycated Hemoglobin/*drug effects
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/metabolism
MH  - Insulin Secretion
MH  - Metformin/therapeutic use
MH  - Peptides/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Receptors, Glucagon/*agonists
MH  - Treatment Outcome
OTO - NOTNLM
OT  - GLP-1
OT  - diabetes mellitus
EDAT- 2014/01/01 06:00
MHDA- 2015/03/10 06:00
CRDT- 2013/12/31 06:00
PHST- 2013/02/14 00:00 [received]
PHST- 2013/04/15 00:00 [revised]
PHST- 2013/10/24 00:00 [accepted]
PHST- 2013/12/31 06:00 [entrez]
PHST- 2014/01/01 06:00 [pubmed]
PHST- 2015/03/10 06:00 [medline]
AID - 10.1111/dom.12253 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2014 Jul;16(7):588-601. doi: 10.1111/dom.12253. Epub 2014 
      Jan 20.